logo

Seattle Genetics Inc. (SGEN)



Trade SGEN now with
  Date
  Headline
9/21/2020 10:26:22 AM Seattle, Genmab Present Data From Tisotumab Vedotin InnovaTV 204 Trial In Recurrent Or Metastatic Cervical Cancer
9/18/2020 6:51:03 AM Seattle Genetics And Astellas Pharma Announce Phase 3 Trial Of PADCEV Meets Primary Endpoint
9/14/2020 6:52:01 AM Seattle Genetics, Merck Announce Strategic Oncology Collaborations; Merck To Buy $1 Bln Equity Stake In Seattle Genetics
8/27/2020 8:13:26 AM Seattle Genetics To Receive Milestone Payment From GlaxoSmithKline Under ADC Collaboration
8/27/2020 8:09:06 AM Seattle Genetics Highlights Data From Broad Oncology Portfolio During ESMO Virtual Congress 2020
8/12/2020 8:05:51 AM Seattle Genetics Says TUKYSA Approved Within Months For All Countries Participating In FDA's Project Orbis Initiative
7/30/2020 4:06:22 PM Seattle Genetics Q2 Loss/share $0.12 Vs. Loss $0.49 Year Ago
6/29/2020 5:02:21 PM Seattle Genetics Announces Positive Topline Results From Phase 2 Trial Of Tisotumab Vedotin In Cervical Cancer
6/18/2020 8:05:02 AM Seattle Genetics Begins Phase 1 Clinical Trials For Two Novel Antibody-Based Drug Candidates
6/1/2020 7:05:38 AM William Blair Reiterates Seattle Genetics Inc. (SGEN) At Outperform
5/29/2020 8:07:36 AM Seattle Genetics Reports Positive Results From Exploratory Analyses Of HER2CLIMB For TUKYSA
5/18/2020 8:02:52 AM Seattle Genetics To Feature Antibody-Drug Conjugate Innovation And Targeted Therapy Programs At AACR Meeting